D.J.A. Lobbezoo

731 citations

14 papers · 490 indexed · h-index 8

Oncology top 10%
Pulmonary and Respiratory Medicine top 10%
Cancer Research top 10%
Radiology, Nuclear Medicine and Imaging
Molecular Biology

Co-authors: Adri C. Voogd Agnès J. van de Wouw Roel J.W. van Kampen Maaike de Boer Vivianne C. G. Tjan‐Heijnen Natascha A. J. B. Peters Frank Peters J.M.G.H. van Riel
Topics: Breast Cancer Treatment Studies (10 papers)HER2/EGFR in Cancer Research (8 papers)Cancer Treatment and Pharmacology (7 papers)
Cited by: Cancer Research Oncology Pulmonary and Respiratory Medicine
Journals: British Journal of Cancer Annals of Oncology European Journal of Cancer
Partner nations: Netherlands United States Curacao

In The Last Decade

D.J.A. Lobbezoo

14 papers receiving 486 citations

Peers

Countries citing papers authored by D.J.A. Lobbezoo

Since Specialization

Citations

This map shows the geographic impact of D.J.A. Lobbezoo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D.J.A. Lobbezoo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D.J.A. Lobbezoo more than expected).

Fields of papers citing papers by D.J.A. Lobbezoo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D.J.A. Lobbezoo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D.J.A. Lobbezoo. The network helps show where D.J.A. Lobbezoo may publish in the future.

Co-authorship network of co-authors of D.J.A. Lobbezoo

This figure shows the co-authorship network connecting the top 25 collaborators of D.J.A. Lobbezoo. A scholar is included among the top collaborators of D.J.A. Lobbezoo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D.J.A. Lobbezoo. D.J.A. Lobbezoo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Improving Outcome-Driven Care in Multiple Myeloma Using Patient-Reported Outcomes: A Qualitative Evaluation Study 2023 ·Patient ·(unknown),Marleen de Mul,Marjolein van der Klift,Annemiek Broijl,Lidwine W. Tick,(unknown),Mirjam M. Garvelink,D.J.A. Lobbezoo,Pieter Sonneveld,Jan A. Hazelzet	3
2	The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry 2022 ·Breast Cancer Research and Treatment ·(unknown),(unknown),D.J.A. Lobbezoo,Ingeborg J. H. Vriens,Loes Kooreman,Frans Erdkamp,M. Wouter Dercksen,Birgit E. P. J. Vriens,(unknown),Manon J. Pepels,(unknown),Jolien Tol,Joan B. Heijns,Agnès J. van de Wouw,Natascha A. J. B. Peters,Ananda Hochstenbach‐Waelen,Marjolein L. Smidt,Sandra M. E. Geurts,Vivianne C. G. Tjan‐Heijnen	1
3	Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry 2020 ·Quality of Life Research ·(unknown),Bram Ramaekers,D.J.A. Lobbezoo,Roel J.W. van Kampen,Maaike de Boer,Agnès J. van de Wouw,M. W. Dercksen,Sandra M. E. Geurts,Manuela Joore,Vivianne C. G. Tjan‐Heijnen	14
4	A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry. 2019 ·The Breast ·(unknown),Sandra M. E. Geurts,(unknown),Sander Croes,Birgit E. P. J. Vriens,Franchette W.P.J. van den Berkmortel,M. Wouter Dercksen,Agnès J. van de Wouw,Manon J. Pepels,(unknown),D.J.A. Lobbezoo,Maaike de Boer,Vivianne C. G. Tjan‐Heijnen	1
5	Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium 2017 ·European Journal of Cancer ·Roel J.W. van Kampen,Bram Ramaekers,D.J.A. Lobbezoo,Maaike de Boer,M. Wouter Dercksen,F. Van den Berkmortel,Tineke J. Smilde,Agnès J. van de Wouw,Frank Peters,(unknown),Natascha A. J. B. Peters,V.C.G. Tjan-Heijnen,Manuela Joore	12
6	A real-world study on implementation of bevacizumab in a cohort of HER2-negative metastatic breast cancer patients: A study of the Southeast Netherlands Breast Cancer Consortium 2017 ·Cancer Treatment and Research Communications ·Roel J.W. van Kampen,D.J.A. Lobbezoo,Maaike de Boer,M. Wouter Dercksen,Adri C. Voogd,F. Van den Berkmortel,Tineke J. Smilde,Agnès J. van de Wouw,Frank Peters,(unknown),Natascha A. J. B. Peters,P.G.M. Peer,Manuela Joore,Vivianne C. G. Tjan‐Heijnen	1
7	The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches 2016 ·Oncotarget ·D.J.A. Lobbezoo,Wilfred Truin,Adri C. Voogd,Rudi M. H. Roumen,Gerard Vreugdenhil,M. Wouter Dercksen,Franchette van den Berkmortel,Tineke J. Smilde,A. van de Wouw,Roel van Kampen,(unknown),Natascha A. J. B. Peters,Petronella G.M. Peer,Vivianne C. G. Tjan‐Heijnen	9
8	Sentinel Lymph Node Biopsy and Isolated Tumor Cells in Invasive Lobular Versus Ductal Breast Cancer 2016 ·Clinical Breast Cancer ·Wilfred Truin,Rudi M. H. Roumen,Sabine Siesling,Margriet van der Heiden‐van der Loo,D.J.A. Lobbezoo,Vivianne C. G. Tjan‐Heijnen,Adri C. Voogd	9
9	Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? 2015 ·British Journal of Cancer ·D.J.A. Lobbezoo,Roel J.W. van Kampen,Adri C. Voogd,M. W. Dercksen,F. Van den Berkmortel,Tineke J. Smilde,Agnès J. van de Wouw,Frank Peters,J.M.G.H. van Riel,Natascha A. J. B. Peters,Maaike de Boer,P.G.M. Peer,Vivianne C. G. Tjan‐Heijnen	169
10	In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium 2015 ·Annals of Oncology ·D.J.A. Lobbezoo,Roel J.W. van Kampen,Adri C. Voogd,M. Wouter Dercksen,F. Van den Berkmortel,TJ Smilde,Agnès J. van de Wouw,Frank Peters,J.M.G.H. van Riel,Natascha A. J. B. Peters,Maaike de Boer,P.G.M. Peer,V.C.G. Tjan-Heijnen	47
11	Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium 2015 ·The Oncologist ·(unknown),D.J.A. Lobbezoo,Maaike de Boer,M. Wouter Dercksen,Franchette van den Berkmortel,Roel J.W. van Kampen,Agnès J. van de Wouw,Bart de Vries,Manuela Joore,Petronella G.M. Peer,Adri C. Voogd,Vivianne C. G. Tjan‐Heijnen	30
12	[Combination of exemestane and everolimus may produce toxic side effects: a new treatment option for metastatic hormone-sensitive breast cancer]. 2014 ·PubMed ·(unknown),Maaike de Boer,D.J.A. Lobbezoo,(unknown),Vivianne C. G. Tjan‐Heijnen	1
13	Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome 2013 ·Breast Cancer Research and Treatment ·D.J.A. Lobbezoo,Roel J.W. van Kampen,Adri C. Voogd,M. Wouter Dercksen,Franchette van den Berkmortel,Tineke J. Smilde,Agnès J. van de Wouw,Frank Peters,J.M.G.H. van Riel,Natascha A. J. B. Peters,Maaike de Boer,George F. Borm,Vivianne C. G. Tjan‐Heijnen	186
14	If there is no overall survival benefit in metastatic breast cancer: Does it imply lack of efficacy? Taxanes as an example 2012 ·Cancer Treatment Reviews ·Birgit E. P. J. Vriens,D.J.A. Lobbezoo,(unknown),Jürgen Veeck,Adri C. Voogd,Vivianne C. G. Tjan‐Heijnen	7

About D.J.A. Lobbezoo

D.J.A. Lobbezoo is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 14 papers that have together received 490 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (10 papers), HER2/EGFR in Cancer Research (8 papers) and Cancer Treatment and Pharmacology (7 papers). The work is most often cited by research in Cancer Research (256 citations), Oncology (378 citations) and Pulmonary and Respiratory Medicine (261 citations). D.J.A. Lobbezoo has collaborated with scholars based in Netherlands, United States and Curacao. Frequent co-authors include Adri C. Voogd, Agnès J. van de Wouw, Roel J.W. van Kampen, Maaike de Boer, Vivianne C. G. Tjan‐Heijnen, Natascha A. J. B. Peters, Frank Peters, J.M.G.H. van Riel, Tineke J. Smilde and M. Wouter Dercksen. Their work appears in journals such as British Journal of Cancer, Annals of Oncology and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact